Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial

2018 ◽  
Vol 24 (4) ◽  
pp. 403-410 ◽  
Author(s):  
Akihiro Tomida ◽  
◽  
Keisuke Uehara ◽  
Kazuhiro Hiramatsu ◽  
Atsuyuki Maeda ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results

scholarly journals Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
M. Kripp ◽  
K. Horisberger ◽  
S. Mai ◽  
P. Kienle ◽  
T. Gaiser ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Phase Ii ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results ◽  
Phase Ii Trials ◽  
Exon 2 ◽  
Significant Difference

Purpose. The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC). We report the long-term results in patients treated within two sequential clinical trials.Methods. Patients receiving neoadjuvant RCT using capecitabine and irinotecan (CapIri) within a phase I/II trial or CapIri + cetuximab within a phase II trial were evaluated for analysis of disease-free survival (DFS) and overall survival (OS). KRAS exon 2 mutational status had been analyzed in patients receiving cetuximab.Results. 37 patients from the CapIri trial and 49 patients from the CapIri-cetuximab treatment group were evaluable. Median follow-up time was 75.2 months. The 5-year DFS rate was 82% (CapIri) and 79% (CapIri-cetuximab)(P=0.62). The median OS was 127.4 months. 5-year OS was 73% for both groups (CapIri and CapIri-cetuximab)(P=0.61). No significant difference in DFS(P=0.86)or OS(P=0.39)was noticed between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS wild-type tumors.Conclusions. As the addition of cetuximab did not improve neither DFS nor OS it should not play a role in the perioperative treatment of patients with LARC, not even of patients with (K)RAS WT tumors.

Long-term Results of the “Liver First” Approach in Patients With Locally Advanced Rectal Cancer and Synchronous Liver Metastases

2013 ◽  
Vol 56 (3) ◽  
pp. 281-287 ◽  
Author(s):  
Ninos Ayez ◽  
Jacobus W. A. Burger ◽  
Anne E. van der Pool ◽  
Alexander M. M. Eggermont ◽  
Dirk J. Grunhagen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Liver Metastases ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results ◽  
Synchronous Liver Metastases

5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results

2006 ◽  
Vol 37 (7) ◽  
pp. 860-865 ◽  
Author(s):  
Salvatore Pucciarelli ◽  
Emanuele Urso ◽  
Gian Luca DeSalvo ◽  
Carlo Aschele ◽  
Maria Luisa Friso ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Surgical Complications ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results

scholarly journals Long-term results of combined treatment of a patient with cancer of the upper ampullary rectum Complicated by bleeding

2020 ◽  
Vol 39 (3) ◽  
pp. 56-59
Author(s):  
Sergey A. Alentyev ◽  
Oleg A. Litvinov ◽  
Evgeniy V. Zhitikhin ◽  
Igor E. Onnitsev ◽  
Igor G. Ignatovich ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Clinical Observation ◽  
Combined Treatment ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results ◽  
Superior Rectal Artery

The clinical observation the results of combined treatment of a patient with locally advanced rectal cancer complicated by bleeding with the use of selective chemooil embolization of the superior rectal artery have been presented (1 figure, bibliography: 4 refs).

Sign in / Sign up

Export Citation Format

Share Document